Startup Dossier
ErVimmune
ErVimmune is an immuno-oncology biotech developing off-the-shelf cancer vaccines and cell therapies targeting so-called cold tumors that do not respond to existing immunotherapies. Leveraging proprietary antigen discovery based on human endogenous retroviruses (HERVs), the company designs shared, non-personalised vaccines for broad patient populations, with a lead candidate targeting triple-negative breast cancer and ovarian cancer.
About
ErVimmune is an immuno-oncology biotech developing off-the-shelf cancer vaccines and cell therapies targeting so-called cold tumors that do not respond to existing immunotherapies. Leveraging proprietary antigen discovery based on human endogenous retroviruses (HERVs), the company designs shared, non-personalised vaccines for broad patient populations, with a lead candidate targeting triple-negative breast cancer and ovarian cancer.
Structural DNA
Legal Name
ErVimmune
SIREN
877916213
Founders & Team
Funding Lineage
Series A
Seventure Partners (Lead)
€17.0M
Jan 2026
Seed
Bpifrance (Lead)
€4.4M
Jan 2023